Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy
A Phase II Randomized Trial of Olaparib NSC-747856 Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER-Negative, Locally Advanced or Metastatic Breast Cancer
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation
A Phase III Double-blind Randomised Study Assessing the Efficacy and
Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line
Treatment for Patients with Histologically Confirmed, Locally Advanced
Inoperable or Metastatic Triple-Negative Breast Cancer TNBC
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
ARM: AXILLARY REVERSE MAPPING ? A PROSPECTIVE TRIAL TO STUDY RATES OF LYMPHEDEMA AND REGIONAL RECURRENCE AFTER SENTINEL LYMPH NODE BIOPSY AND SENTINEL LYMPH NODE BIOPSY FOLLOWED BY AXILLARY LYMPH NODE DISSECTION WITH AND WITHOUT AXILLARY REVERSE MAPPING